

FINAL EXAM
JUNE 2018

NATIONAL BOARD OF EXAMINATIONS

SURGICAL ONCOLOGY

PAPER-I

SURGONCO/J/18/47/I

Time: 3 hours

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. What are the specimen requirements for molecular diagnostics and cytogenetics? What is the importance of cytogenetics testing in diagnosis of soft tissue sarcoma? 4+6
2. Enumerate cancers attributable to tobacco smoking according to level of evidence available. Add a note on carcinogenic substances present in tobacco products and their role in carcinogenesis. 2+(3+5)
3. Discuss the basis for fractionation in radiation therapy and its types with examples and current applications. 2+3+5
4. What is targeted therapy? What is the role of targeted therapy in the management of non-metastatic solid organ malignancies with examples? 2+8
5. Discuss various criteria and tools available for assessing the clinical response. Add a note on predictive Serum Biomarkers. 7+3
6. What is Meta-analysis? How does it differ from systematic review? Discuss results of any one meta-analysis each in Head and neck and Breast Cancer. 2+4+4
7. Discuss the principle and various approaches to Mandibular preservation with respect to indications, contraindications, advantages and disadvantages. 10
8. What are the rehabilitation concerns in a patient undergoing total maxillectomy? How will you address each one of them? 4+6
9. Mutational landscape of colorectal cancer and its therapeutic implications. 5+5
10. Discuss the changes in 8th edition of AJCC/TNM staging of cancers and discuss the staging of oral, lung, colorectal and gallbladder cancer. 2+2+2+2+2
